Is AFMD stock a buy for an oversold bounce?

AFMD stock can be considered for a tactical oversold bounce with strict risk controls. We suggest small position sizes, entry near **$0.18**, and profit-taking around **$0.30** unless new positive clinical news appears.

What are the main risks for AFMD stock?

Major risks include trial failures, dilution from capital raises, thin liquidity, and negative earnings (EPS **-5.09**). These can send shares lower quickly; use tight stops and limit exposure.

How does Meyka AI rate AFMD stock?

Meyka AI rates AFMD with a score out of 100: **58.46 | Grade C+ | Suggestion: HOLD**. The grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

What short-term price target does Meyka AI forecast for AFMD stock?

Meyka AI's forecast model projects a short-term mean-reversion target of **$0.30** for AFMD stock (implied upside **+65.26%** vs current **$0.18**). Forecasts are model-based projections and not guarantees.

US Stocks

Pre-market 21 Jan 2026 AFMD Affimed N.V. (NASDAQ): $0.18 oversold bounce setup

ByDanny Kontos January 21, 2026January 21, 2026

We see AFMD stock trading at $0.18 in the pre-market on 21 Jan 2026, with heavy intraday volume signalling short-term interest. This oversold bounce setup follows a steep multi-month decline from a 52-week high of $8.95 to a 52-week low of $0.02. We outline the technical trigger, key fundamentals, risk points, and a concise trading plan for NASDAQ-listed Affimed N.V. (United States, USD). Our view is tactical: look for a contained rebound, not a trend reversal.